Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00116441

Enrollment

Registered

2005-06-30

Start date

2000-10-31

Completion date

2004-10-31

Last updated

2007-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Multiple Myeloma, Cancer, PSCT, Peripheral Stem Cell Transplant, Chemotherapy, GVAX

Brief summary

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Interventions

BIOLOGICALTherapeutic Cellular Vaccine, GM-CSF Producing

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* De novo multiple myeloma * ECOG 0-2 * No serious co-morbid illnesses and adequate organ function * \> 4 weeks from systemic steroids

Exclusion criteria

* No existing secondary malignancies and no history of secondary malignancies in the past 5 years * No active autoimmune disease

Design outcomes

Primary

Measure	Time frame
Multiple myeloma	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026